These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 34282868)

  • 1. May COVID-19 infection induce a paradoxical improvement of a non-responsive case of hidradenitis suppurativa?
    Caposiena Caro RD; Pensa C; Lambiase S; Candi E; Bianchi L
    Ital J Dermatol Venerol; 2021 Oct; 156(5):616-617. PubMed ID: 34282868
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic.
    Kearns DG; Chat VS; Uppal S; Wu JJ
    J Am Acad Dermatol; 2020 Dec; 83(6):e433-e434. PubMed ID: 32735966
    [No Abstract]   [Full Text] [Related]  

  • 3. Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?
    Rosi E; Pimpinelli N; Prignano F
    J Dermatolog Treat; 2022 Feb; 33(1):599. PubMed ID: 32432955
    [No Abstract]   [Full Text] [Related]  

  • 4. Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations.
    Blaszczak A; Trinidad JCL; Cartron AM
    J Am Acad Dermatol; 2020 Jul; 83(1):e31. PubMed ID: 32283230
    [No Abstract]   [Full Text] [Related]  

  • 5. Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic.
    Yim RM; Singh I; Armstrong AW
    Dermatol Online J; 2020 Oct; 26(10):. PubMed ID: 33147660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic.
    Benesh G; Andriano TM; Babbush KM; Hosgood HD; Cohen SR
    J Cutan Med Surg; 2021; 25(4):446-448. PubMed ID: 33625899
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy.
    Molinelli E; Diotallevi F; Simonetti O; Brisigotti V; Sapigni C; Radi G; Campanati A; Offidani A
    Dermatol Ther; 2020 Nov; 33(6):e14256. PubMed ID: 32860474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the risk of severe COVID-19 infection in patients with hidradenitis suppurativa.
    Seltzer JA; Okeke CAV; Perry JD; Shipman WD; Okoye GA; Byrd AS
    J Am Acad Dermatol; 2020 Aug; 83(2):e153-e154. PubMed ID: 32389715
    [No Abstract]   [Full Text] [Related]  

  • 9. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
    Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
    J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience in patients with hidradenitis suppurativa and COVID-19 symptoms.
    Galán JL; Silvente C; González M; García C; Díez K; Martín MÁ; Velázquez D; de la Cueva P
    J Am Acad Dermatol; 2020 Oct; 83(4):e309-e311. PubMed ID: 32603717
    [No Abstract]   [Full Text] [Related]  

  • 11. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
    Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
    Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hidradenitis suppurativa and adalimumab in the COVID-19 era.
    Marzano AV; Moltrasio C; Genovese G; Muratori S; Dapavo P; Fabbrocini G; Patrizi A; Sechi A; Micali G; Pellegrino M; Gisondi P; Dini V; Bianchi L; Fania L; Offidani A; Prignano F; Atzori L; Miraglia E; Cannavò SP; Bettoli V; Stingeni L; Balestri R; Venturini M; Peris K
    Eur J Dermatol; 2020 Dec; 30(6):748-749. PubMed ID: 33337329
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?
    Patsatsi A; Kyriakou A
    Clin Dermatol; 2021; 39(1):52-55. PubMed ID: 33972053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of patients with hidradenitis suppurativa during the COVID-19 pandemic.
    Montero-Vilchez T; Martinez-Lopez A; Salvador-Rodriguez L; Molina-Leyva A; Arias-Santiago S
    Dermatol Ther; 2020 Nov; 33(6):e13875. PubMed ID: 32558071
    [No Abstract]   [Full Text] [Related]  

  • 15. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.
    Faivre C; Villani AP; Aubin F; Lipsker D; Bottaro M; Cohen JD; Durupt F; Jeudy G; Sbidian E; Toussirot E; Badot V; Barbarot S; Debarbieux S; Delaporte E; Goegebeur G; Morel J; Nassif A; Duru G; Jullien D;
    J Am Acad Dermatol; 2016 Jun; 74(6):1153-9. PubMed ID: 26965410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hidradenitis suppurativa: The importance of virtual outpatient care during COVID-19 pandemic.
    Shah M; Naik HB; Alhusayen R
    J Am Acad Dermatol; 2020 Jul; 83(1):e81-e82. PubMed ID: 32360857
    [No Abstract]   [Full Text] [Related]  

  • 17. Hidradenitis suppurativa in Crohn's disease during adalimumab therapy: a paradox?
    Martina E; Campanati A; Giuliodori K; Offidani A
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Mar; 26(1):21-23. PubMed ID: 28352932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of hidradenitis suppurativa in a patient treated with ustekinumab for her psoriasis: A potential paradoxical reaction?
    Gkini MA; Bewley AP
    Dermatol Ther; 2018 Nov; 31(6):e12742. PubMed ID: 30221819
    [No Abstract]   [Full Text] [Related]  

  • 19. Paradoxical psoriasiform reactions to antitumour necrosis factor-α drugs in hidradenitis suppurativa.
    Dequidt L; Cogrel O; Guillet S; Milpied B; Darrigade AS; Beylot-Barry M; Pham-Ledard A
    Br J Dermatol; 2018 Jan; 178(1):281-283. PubMed ID: 28444990
    [No Abstract]   [Full Text] [Related]  

  • 20. Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy.
    Marasca C; Ruggiero A; Megna M; Annunziata MC; Fabbrocini G
    J Dermatolog Treat; 2022 Feb; 33(1):592. PubMed ID: 32403954
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.